Treatment of neuropsychiatric symptoms in Alzheimer's disease;Tratamiento de los síntomas neuropsíquiátricos en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 35, Issue 9, 2002, Pages 846-850

  Kaufer, Daniel ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Anticonvulsivants; Antidepressants; Antipsychotics; Cholinesterase inhibitors

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; THIORIDAZINE; TRAZODONE; VALPROATE SEMISODIUM;

AGGRESSION; ALZHEIMER DISEASE; ANXIETY DISORDER; APATHY; CAREGIVER; CONFERENCE PAPER; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; EVALUATION; HALLUCINATION; HUMAN; MENTAL DISEASE; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; SYMPTOM; TITRIMETRY;

EID: 17944387565     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3509.2002003     Document Type: Conference Paper

References (33)

1. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. The Neuropsychiatric Inventory Questionnaire (NPI-Q): Validation of a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233-9.
2. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46: 130-5.
3. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, MacMillan A, et al. Assessing the impact of behavioral disturbances in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. JAGS 1998; 46: 210-5.
4. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm (Gen Sect) 1993; 91: 135-59.
5. Raskind MA, Peskind ER. Neurologic bases of noncognitive behavioral problems in Alzheimer's disease. Alz Dis Assoc Disord 1994; 8 (Suppl 3): 54-60.
6. Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996; 47: 876-83.
7. Cummings JL, Victoroff JL. Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry Nenropsychol Behav Neurol 1990; 3: 140-58.
8. Cummings JL, Mega M, Gray K, Rosenberg-Thomson S, Carusi DA, Gerabein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
9. Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995; 35: 771-91.
10. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric problems and nursing home placement in of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-51.
11. O'Donnell BF, Drachman DA, Barnes HJ, Petersen KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5: 45-52.
12. Mittleman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer's disease: A randomized controlled trial. JAMA 1996; 276: 1725-31.
13. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al, and the CERAD Behavioral Pathology Committee. The CERAD Behavioral Rating Scale for Dementia (BRSD). Am J Psychiatry 1995; 152: 1349-57.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
15. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotis A. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry 1987; 48: 9-15.
16. Teri L, Truax P, Logsdon R, Uomoto J, Zarit S, Vitaliano PP. Assessment of behavioral problems in dementia: The revised memory and behavior problems checklist. Psychol Aging 1992; 7: 622-31.
17. Kaufer DI, Pollock BG, Catt KE, López OL, DeKosky ST. An open-label study of donepezil in Alzheimer's Disease: Neuropsychiatric symptom responses and earegiver distress. Neurology 1998; 50 (Suppl 4): A89.
18. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63.
19. Lanctot KL, Best TS, Mittmann N, Liu BA, Oh PI, Einarson TR, Naranjo CA, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550-61.
20. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107-15.
21. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Erikson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
22. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine in the Treatment of Psychosis and Behavioral Disturbances Associated with Alzheimer's Disease [abstract]. American Psychiatric Association 1999.
23. McManus DQ, Arvantis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study group. J Clin Psychiatry 1999; 60: 292-8.
24. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BJ, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30.
25. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997; 54: 836-40.
26. Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1995; 56: 514-8.
27. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry 1990; 157: 894-901.
28. Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other nonneuroleptic treatment of agitation in dementia. J Geriatr Psychiatry Neurol 1995; 8 (Suppl 1): S28-S39.
29. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1: 82-4.
30. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998; 13: 100-8.
31. Rubin EH, Morris JC, Storandt M, Berg L. Behavioral changes in patients with mild senile dementia of the Alzheimer's type. Psychiatry Res 1986; 21: 55-62.
32. Kaufer DI, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10: 55-63.
33. Kaufer DI. Beyond the cholinergic hypothesis. The effect of metrifonate and other cholinesterase-inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Demen Geriatr Cogn Disord 1998; 9 (Suppl 2): 8-14.